{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T21:53:39Z","timestamp":1765835619297,"version":"3.48.0"},"reference-count":50,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"unspecified","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01DA047952"],"award-info":[{"award-number":["R01DA047952"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR001998"],"award-info":[{"award-number":["UL1TR001998"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2021,6,8]]},"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The overall goal of the Kentucky Viral Hepatitis Treatment Study (KeY Treat) is to eliminate hepatitis C transmission from a county in Appalachian Kentucky by removing the barriers to accessing hepatitis C virus (HCV) treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods\/analysis<\/jats:title>\n                    <jats:p>KeY Treat is a phase IV, open-label, single-arm clinical trial of sofosbuvir\/velpatasvir (SOF\/VEL) for the treatment of viraemic HCV infections. Those eligible for KeY Treat are at least 18 years of age, viraemic and are residents of the target county. Pregnant women are not eligible. Rapid HCV RNA screening is used to determine eligibility, and those with a quantifiable viral load (VL) consenting to participate initiate SOF\/VEL on the same day. All pharmacologic treatment and related medical care is provided free of charge using a non-specialist provider model. Follow-up visits occur at 2, 6 and 12 weeks during treatment to assess medication adherence (measured via VL and self-report), side effects and engagement in risk behaviours. Post-treatment visits occur at 12\u2009weeks (sustained virologic response (SVR12) visit), 6\u2009months and 12\u2009months post-treatment completion to assess re-infection. A control county has also been identified, and prevalence and incidence of chronic HCV infections will be compared with the target community longitudinally. The primary outcome to assess elimination is SVR12. However, several outcomes will be measured to assess the effectiveness of removing the barriers to HCV treatment, including treatment entry, completion and re-infection. Analyses will be conducted via a generalised linear model framework that can incorporate flexible covariate adjustment and multiple outcome types with a compatible link function. Mathematical modelling will be completed assessing the impact and cost-effectiveness of the intervention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>KeY Treat has been approved by the Institutional Review Board at the University of Kentucky. Results from KeY Treat will be presented at conferences and published in peer-reviewed journals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" specific-use=\"clinicaltrial pre-results\" xlink:href=\"NCT03949764\">NCT03949764<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2020-041490","type":"journal-article","created":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T12:01:15Z","timestamp":1625486475000},"page":"e041490","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Eliminating hepatitis C in a rural Appalachian county: protocol for the Kentucky Viral Hepatitis Treatment Study (KeY Treat), a phase IV, single-arm, open-label trial of sofosbuvir\/velpatasvir for the treatment of hepatitis C"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct03949764","registry":"10.18810\/clinical-trials-gov","type":"preResults"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1753-7280","authenticated-orcid":false,"given":"Jennifer R","family":"Havens","sequence":"first","affiliation":[{"name":"Behavioral Science, University of Kentucky College of Medicine, Lexington, Kentucky, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takako","family":"Schaninger","sequence":"additional","affiliation":[{"name":"Infectious Diseases, University of Kentucky College of Medicine, Lexington, Kentucky, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Fraser","sequence":"additional","affiliation":[{"name":"Population Health Sciences, University of Bristol, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Lofwall","sequence":"additional","affiliation":[{"name":"Behavioral Science, University of Kentucky College of Medicine, Lexington, Kentucky, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Staton","sequence":"additional","affiliation":[{"name":"Behavioral Science, University of Kentucky College of Medicine, Lexington, Kentucky, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"April M","family":"Young","sequence":"additional","affiliation":[{"name":"Epidemiology, University of Kentucky College of Public Health, Lexington, Kentucky, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ardis","family":"Hoven","sequence":"additional","affiliation":[{"name":"Infectious Diseases, University of Kentucky College of Medicine, Lexington, Kentucky, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon L","family":"Walsh","sequence":"additional","affiliation":[{"name":"Behavioral Science, University of Kentucky College of Medicine, Lexington, Kentucky, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Vickerman","sequence":"additional","affiliation":[{"name":"Population Health Sciences, University of Bristol, Bristol, UK"},{"name":"London School of Hygiene & Tropical Medicine, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,7,5]]},"reference":[{"key":"2025121513520420000_11.7.e041490.1","doi-asserted-by":"publisher","DOI":"10.1053\/jlts.2003.50073"},{"key":"2025121513520420000_11.7.e041490.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1006613"},{"key":"2025121513520420000_11.7.e041490.3","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2013.107"},{"key":"2025121513520420000_11.7.e041490.4","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.idc.2018.02.010","article-title":"Hepatitis C virus diagnosis and the Holy Grail","volume":"32","author":"Applegate","year":"2018","journal-title":"Infect Dis Clin North Am"},{"key":"2025121513520420000_11.7.e041490.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2017.10.009"},{"key":"2025121513520420000_11.7.e041490.6","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.10.005"},{"key":"2025121513520420000_11.7.e041490.7","doi-asserted-by":"publisher","DOI":"10.1007\/s11894-002-0034-y"},{"key":"2025121513520420000_11.7.e041490.8","doi-asserted-by":"publisher","DOI":"10.7326\/M16-2575"},{"key":"2025121513520420000_11.7.e041490.9","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1053\/j.gastro.2018.10.024","article-title":"Status of direct-acting antiviral therapy for hepatitis C virus infection and remaining challenges","volume":"156","author":"Baumert","year":"2019","journal-title":"Gastroenterology"},{"key":"2025121513520420000_11.7.e041490.10","doi-asserted-by":"crossref","first-page":"132","DOI":"10.12688\/wellcomeopenres.15411.1","article-title":"Treatment optimisation for hepatitis C in the era of combination direct-acting antiviral therapy: a systematic review and meta-analysis","volume":"4","author":"Jones","year":"2019","journal-title":"Wellcome Open Res"},{"key":"2025121513520420000_11.7.e041490.11","first-page":"259","article-title":"Patient-Reported outcomes with direct-acting antivirals for the treatment of chronic hepatitis C: current knowledge and outstanding issues","volume":"11","author":"Marcellin","year":"2017","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2025121513520420000_11.7.e041490.12","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1111\/liv.14152","article-title":"Staying hepatitis C negative: a systematic review and meta-analysis of cure and reinfection in people who inject drugs","volume":"39","author":"Latham","year":"2019","journal-title":"Liver Int"},{"key":"2025121513520420000_11.7.e041490.13","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/liv.13949","article-title":"Hepatitis C elimination among people who inject drugs: challenges and recommendations for action within a health systems framework","volume":"39","author":"Day","year":"2019","journal-title":"Liver Int"},{"key":"2025121513520420000_11.7.e041490.14","doi-asserted-by":"crossref","DOI":"10.7448\/IAS.20.1.22146","article-title":"Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there?","volume":"20","author":"Grebely","year":"2017","journal-title":"J Int AIDS Soc"},{"key":"2025121513520420000_11.7.e041490.15","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S2468-1253(16)30075-9","article-title":"Hepatitis C treatment as prevention: evidence, feasibility, and challenges","volume":"1","author":"Hajarizadeh","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025121513520420000_11.7.e041490.16","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26431"},{"key":"2025121513520420000_11.7.e041490.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.02.007"},{"key":"2025121513520420000_11.7.e041490.18","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1111\/add.14731","article-title":"Cost-Effectiveness of scaling-up HCV prevention and treatment in the United States for people who inject drugs","volume":"114","author":"Barbosa","year":"2019","journal-title":"Addiction"},{"key":"2025121513520420000_11.7.e041490.19","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.drugalcdep.2019.02.008","article-title":"Treatment cascade for hepatitis C virus in young adult people who inject drugs in San Francisco: low number treated","volume":"198","author":"Morris","year":"2019","journal-title":"Drug Alcohol Depend"},{"key":"2025121513520420000_11.7.e041490.20","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.drugpo.2015.05.007","article-title":"Human rights and access to hepatitis C treatment for people who inject drugs","volume":"26","author":"Wolfe","year":"2015","journal-title":"Int J Drug Policy"},{"key":"2025121513520420000_11.7.e041490.21","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/jvh.13119","article-title":"Perceived barriers related to testing, management and treatment of HCV infection among physicians prescribing opioid agonist therapy: the C-SCOPE study","volume":"26","author":"Litwin","year":"2019","journal-title":"J Viral Hepat"},{"key":"2025121513520420000_11.7.e041490.22","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/JXX.0000000000000269","article-title":"Promoting treatment for hepatitis C in people who inject drugs: a review of the barriers and opportunities","volume":"32","author":"Pedlar","year":"2020","journal-title":"J Am Assoc Nurse Pract"},{"key":"2025121513520420000_11.7.e041490.23","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S2468-1253(19)30085-8","article-title":"The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study","volume":"4","author":"Trickey","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025121513520420000_11.7.e041490.24","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/add.13948","article-title":"Scaling-up HCV prevention and treatment interventions in rural United States-model projections for tackling an increasing epidemic","volume":"113","author":"Fraser","year":"2018","journal-title":"Addiction"},{"key":"2025121513520420000_11.7.e041490.25","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/add.14012","article-title":"Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a cochrane review and meta-analysis","volume":"113","author":"Platt","year":"2018","journal-title":"Addiction"},{"key":"2025121513520420000_11.7.e041490.26","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/aje\/kwz097","article-title":"Scaling up hepatitis C prevention and treatment interventions for achieving elimination in the United States: a rural and urban comparison","volume":"188","author":"Fraser","year":"2019","journal-title":"Am J Epidemiol"},{"key":"2025121513520420000_11.7.e041490.27","first-page":"453","article-title":"Increases in hepatitis C virus infection related to injection drug use among persons aged \u226430 years - Kentucky, Tennessee, Virginia, and West Virginia, 2006-2012","volume":"64","author":"Zibbell","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025121513520420000_11.7.e041490.28","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.6371","article-title":"Prevalence of hepatitis C virus infection in US states and the district of Columbia, 2013 to 2016","volume":"1","author":"Rosenberg","year":"2018","journal-title":"JAMA Netw Open"},{"key":"2025121513520420000_11.7.e041490.29","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.2105\/AJPH.2012.300874","article-title":"Individual and network factors associated with prevalent hepatitis C infection among rural Appalachian injection drug users","volume":"103","author":"Havens","year":"2013","journal-title":"Am J Public Health"},{"key":"2025121513520420000_11.7.e041490.30","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/08897077.2019.1635555","article-title":"The opioid and related drug epidemics in rural Appalachia: a systematic review of populations affected, risk factors, and infectious diseases","volume":"41","author":"Schalkoff","year":"2020","journal-title":"Subst Abus"},{"key":"2025121513520420000_11.7.e041490.31","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2013.301812"},{"key":"2025121513520420000_11.7.e041490.32","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2017.304132"},{"key":"2025121513520420000_11.7.e041490.33","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-018-0390-3"},{"key":"2025121513520420000_11.7.e041490.34","first-page":"443","article-title":"Community Outbreak of HIV Infection Linked to Injection Drug Use of Oxymorphone--Indiana, 2015","volume":"64","author":"Conrad","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025121513520420000_11.7.e041490.35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1515195"},{"key":"2025121513520420000_11.7.e041490.36","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ebiom.2018.10.007","article-title":"A large HCV transmission network enabled a fast-growing HIV outbreak in rural Indiana, 2015","volume":"37","author":"Ramachandran","year":"2018","journal-title":"EBioMedicine"},{"key":"2025121513520420000_11.7.e041490.37","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00485-5"},{"key":"2025121513520420000_11.7.e041490.38","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/QAI.0000000000001098","article-title":"County-Level vulnerability assessment for rapid dissemination of HIV or HCV infections among persons who inject drugs, United States","volume":"73","author":"Van Handel","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025121513520420000_11.7.e041490.39","doi-asserted-by":"crossref","first-page":"529","DOI":"10.15585\/mmwr.mm6718a5","article-title":"Access to syringe services programs - Kentucky, North Carolina, and West Virginia, 2013-2017","volume":"67","author":"Bixler","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025121513520420000_11.7.e041490.40","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.23252"},{"key":"2025121513520420000_11.7.e041490.41","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.drugpo.2017.05.045","article-title":"Healthcare contact and treatment uptake following hepatitis C virus screening and counseling among rural Appalachian people who use drugs","volume":"47","author":"Stephens","year":"2017","journal-title":"Int J Drug Policy"},{"key":"2025121513520420000_11.7.e041490.42","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s10935-017-0483-6","article-title":"Silence surrounding hepatitis C status in risk relationships among rural people who use drugs","volume":"38","author":"Hofmeister","year":"2017","journal-title":"J Prim Prev"},{"key":"2025121513520420000_11.7.e041490.43","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-012-0371-2"},{"key":"2025121513520420000_11.7.e041490.44","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1108\/IJPH-03-2017-0012","article-title":"Hepatitis C antibody reactivity among high-risk rural women: opportunities for services and treatment in the criminal justice system","volume":"14","author":"Strickland","year":"2018","journal-title":"Int J Prison Health"},{"key":"2025121513520420000_11.7.e041490.45","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28571"},{"key":"2025121513520420000_11.7.e041490.46","doi-asserted-by":"crossref","first-page":"213","DOI":"10.14423\/SMJ.0000000000000794","article-title":"A Social-Ecological review of cancer disparities in Kentucky","volume":"111","author":"Rodriguez","year":"2018","journal-title":"South Med J"},{"key":"2025121513520420000_11.7.e041490.47","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x"},{"key":"2025121513520420000_11.7.e041490.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2006.09.002"},{"key":"2025121513520420000_11.7.e041490.49","doi-asserted-by":"publisher","DOI":"10.1037\/\/0893-164X.9.4.242"},{"key":"2025121513520420000_11.7.e041490.50","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2771"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2020-041490","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T21:52:17Z","timestamp":1765835537000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2020-041490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":50,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7,5]]},"published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1136\/bmjopen-2020-041490"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2020-041490","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}